Mode
Text Size
Log in / Sign up
Phase 2 Completed N=24 Treatment

An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents

Cannabis Dependence
Source: ClinicalTrials.gov NCT00542750 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
May 2018
Primary outcomePrimary: Feasibility of Recruitment, Measured by Number of Participants Recruited and Retained During Study Period — 24 Participants

Summary

The purpose of this pilot study is to determine the feasibility of conducting a trial of N-Acetylcysteine in cannabis dependent adolescents.

Outcome Measures

OutcomeResultp-value
PRIMARY
Feasibility of Recruitment, Measured by Number of Participants Recruited and Retained During Study Period
24

Eligibility Criteria

Inclusion Criteria

  • Male or female, 12 - 20 years old.
  • Participants must be regular smokers of marijuana (on average smoke at least 3 times per week for at least one year) and meet DSM-IV Criteria for cannabis dependence, with desire to cut down on marijuana use.
  • Participants must understand all oral and written informed consent and give such consent prior to on-site screening.
  • Participants must agree to refrain from marijuana use for 24 hours prior to each cue reactivity session (Visits 2 and 4).
  • Participants must have a person that can be contacted in case of emergency.
  • Participants must have had stable residence for the past 30 days.
  • Post-menarchal female participants must agree to use birth control to avoid pregnancy.

Exclusion Criteria

  • Allergy or intolerance to N-Acetylcysteine (NAC).
  • Pregnancy or lactation.
  • History of seizures.
  • Current or past history of asthma and/or the occasional or daily use of albuterol or other beta-agonist inhalers.
  • Current use of medications that might affect heart rate or skin conductance.
  • Use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous if taken with NAC) within 14 days of study.
  • History of significant hepatic, renal, endocrine, cardiac (i.e., arrhythmia requiring medication, angina pectoris, myocardial infarction,), stroke, seizure, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, metabolic, or other disorders that may place the participant at increased risk per the judgment of the study physician.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00542750). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search